FDA
-
-
-
-
-
-
-
Endologix Announces Completion of Enrollment in the EVAS2 Confirmatory Clinical Study to Evaluate the Nellix EndoVascular Aneurysm Sealing System
-
-
-
-
-
-
-
Endologix, Inc. Comments on Recent FDA Update on Type III Endoleaks with AFX® Endovascular AAA System
-
-
-
-
-
-
-
After-Hours Stock Movers 10/02: (ELGX) (ULBI) (JCP) Higher; (DTEA) (KALA) (EPZM) Lower (more...)
-
-
-
-
-
-
-
Endologix (ELGX) Reports Enrollment of 1st Patient in EVAS2 IDE Clinical Study
-
-
-
-
-
-
-
Endologix (ELGX) Names John Onopchenko as COO
-
-
-
-
-
-
-
Endologix Provides an Update on the Nellix® Endovascular Aneurysm Sealing System U.S. Regulatory Status
-
-
-
-
-
-
-
Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Endologix, Inc. Investors and Encourages Investors to Contact the Firm
-
251,403 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All